

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

#### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)									
1. Name and Address of Reporting Person <sup>*</sup> – Hansen David K		2. Date of Event Requiring Statement (Month/Day/Year) 09/30/2011		3. Issuer Name and Ticker or Trading Symbol AxoGen, Inc. [AXGN]					
(Last) (First) (Middle C/O AXOGEN, INC., 13859 PROGRESS BOULEVARD, SUITE (Street)	)	-09/30/2011		4. Relationship of Reporting Pers Issuer (Check all applicable) Director X_Officer (give title below) Corporate Controller		to 5. If Amendment, Date Original Filed(Month/Day/Year) 10/11/2011 6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person			
ALACHUA, FL 32615		Corporate Controller							
(City) (State) (Zip)		Table I - Non-Derivative Securities Beneficially Owned							
1.Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4) 2. Amount of Securities (Instr. 4) 3. Ownership Form: Direct (I) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)					t Beneficial Ownership		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)   Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1473 (7-02)   Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) SEC 1473 (7-02)									
(Instr. 4) Expira		ation Date Sec		Amount of nderlying ecurity	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Í	Direct (D) or Indirect (I) (Instr. 5)			
Employee Stock Option (right to buy)	06/07/2006	06/07/2016	Common Stock	4,752 (1) (2)	\$ 0.2683 ( <u>3</u> ) ( <u>4</u> )	D			
Employee Stock Option (right to buy)	04/27/2007	04/27/2017	Common Stock	932 (1) (2)	\$ 0.2683 ( <u>3</u> ) ( <u>4</u> )	D			
Employee Stock Option (right to buy)	12/06/2007	12/06/2017	Common Stock	634 <u>(2) (5)</u>	\$ 0.2683 <sup>(3)</sup> (4)	D			
Employee Stock Option (right to buy)	11/18/2008	11/18/2018	Common Stock	327 (2) (6)	\$ 0.2683 <sup>(3)</sup> (4)	D			
Employee Stock Option (right to buy)	06/09/2010	06/09/2020	Common Stock	3,177 (2) (7)	\$ 0.2683 ( <u>3</u> ) ( <u>4</u> )	D			

## **Reporting Owners**

	Relationships				
Reporting Owner Name / Address		10% Owner	Officer	Other	
Hansen David K C/O AXOGEN, INC. 13859 PROGRESS BOULEVARD, SUITE 100 ALACHUA, FL 32615			Corporate Controller		

### Signatures

/s/ David Hansen	03/22/2012
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 100% of the options have vested.
- (2) These options vest semi-annually over four years from the date of grant.
- (3) Amended to correct mistake in option exercise price after appropriate application of conversion ratio as explained in footnotes.
- Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub merger with and into AC, with AC continuing ofter the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was
- (4) merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each share of AC common stock converted into 0.03727336 share of LecTec common stock at the effective time of the Merger. In connection with the Merger, each option to purchase shares of AC common stock was converted tor an option to purchase 0.03727336 of a share of AxoGen common stock.
- (5) 555 options have vested, and 79 options are unvested.
- (6) 204 options have vested, and 123 options are unvested.
- (7) 794 options have vested, and 2,383 options are unvested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.